This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Oatis W, Shankaran V, Saghir F, Bennett CL, Richey E, Bussel JB.A predictive cost-effectiveness analysis of the treatment of chronic, refractory immune thrombocytopenic purpura (ITP) with novel agents: an economic model based on long-term treatment data with rituximab versus romiplostim. 50th Annual Meeting and Exposition of the American Society of Hematology: abstr. 3433, 8 Dec 2008. Available from: URL: http://www.hematology.org
Rights and permissions
About this article
Cite this article
Romiplostim pricing predicted for cost effectiveness. Pharmacoecon. Outcomes News 569, 3 (2009). https://doi.org/10.2165/00151234-200905690-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905690-00008